Omeros Corporation (NASDAQ:OMER) – Analysts at Wedbush reduced their Q2 2018 earnings estimates for shares of Omeros Corporation in a research note issued to investors on Friday. Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will post earnings per share of $0.03 for the quarter, down from their previous estimate of $0.09. Wedbush has a “Outperform” rating and a $47.00 price target on the stock. Wedbush also issued estimates for Omeros Corporation’s Q3 2018 earnings at $0.14 EPS and Q4 2018 earnings at $0.18 EPS.

Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.12. The company had revenue of $17.15 million for the quarter, compared to analyst estimates of $14.63 million. The firm’s quarterly revenue was up 71.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.32) earnings per share.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/08/21/q2-2018-eps-estimates-for-omeros-corporation-reduced-by-analyst-omer.html.

Several other analysts have also recently weighed in on OMER. Cantor Fitzgerald cut shares of Omeros Corporation from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $21.00 to $15.00 in a research report on Thursday, May 11th. Maxim Group set a $23.00 price objective on shares of Omeros Corporation and gave the company a “buy” rating in a research report on Thursday, May 11th. ValuEngine upgraded shares of Omeros Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Cowen and Company restated an “outperform” rating on shares of Omeros Corporation in a research report on Saturday, June 3rd. Finally, WBB Securities restated a “strong-buy” rating and set a $75.00 price objective on shares of Omeros Corporation in a research report on Wednesday, June 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Omeros Corporation has an average rating of “Buy” and a consensus price target of $32.80.

Omeros Corporation (NASDAQ:OMER) opened at 22.03 on Monday. The firm’s market capitalization is $987.01 million. Omeros Corporation has a one year low of $7.20 and a one year high of $27.09. The stock’s 50 day moving average is $21.52 and its 200 day moving average is $16.64.

Several institutional investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. boosted its position in Omeros Corporation by 62.4% in the first quarter. UBS Asset Management Americas Inc. now owns 46,539 shares of the biopharmaceutical company’s stock worth $704,000 after buying an additional 17,885 shares during the last quarter. Swiss National Bank boosted its position in Omeros Corporation by 5.7% in the first quarter. Swiss National Bank now owns 67,100 shares of the biopharmaceutical company’s stock worth $1,015,000 after buying an additional 3,600 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Omeros Corporation by 2.8% in the first quarter. Bank of New York Mellon Corp now owns 225,583 shares of the biopharmaceutical company’s stock worth $3,411,000 after buying an additional 6,043 shares during the last quarter. Sheaff Brock Investment Advisors LLC boosted its position in Omeros Corporation by 21.7% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 28,000 shares of the biopharmaceutical company’s stock worth $423,000 after buying an additional 5,000 shares during the last quarter. Finally, Chicago Equity Partners LLC purchased a new position in Omeros Corporation during the first quarter worth about $639,000. Hedge funds and other institutional investors own 43.94% of the company’s stock.

In other Omeros Corporation news, VP Michael A. Jacobsen sold 12,000 shares of the business’s stock in a transaction dated Friday, June 16th. The shares were sold at an average price of $24.95, for a total value of $299,400.00. Following the transaction, the vice president now owns 19,500 shares in the company, valued at $486,525. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Michael A. Jacobsen sold 24,000 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $21.20, for a total transaction of $508,800.00. Following the completion of the transaction, the vice president now owns 2,650 shares in the company, valued at approximately $56,180. The disclosure for this sale can be found here. 13.60% of the stock is owned by company insiders.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Earnings History and Estimates for Omeros Corporation (NASDAQ:OMER)

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.